Chimeric antigen receptor redirected T cells (CAR-T cells) have achieved inspiring
outcomes in patients with B cell malignancies, and are now being investigated in other …

Chimeric antigen receptor (CAR) T cell therapies have evolved from a research tool to a
concept-shifting therapy with impressive responses in B cell malignancies. This Review …

Simple Summary Chimeric antigen receptors (CAR) are engineered molecules expressed
on the cell surface that can recognise specific proteins and deliver an activation signal to the …

Chimeric antigen receptor T (CAR-T) cell therapy is regarded as an effective solution for
relapsed or refractory tumors, particularly for hematological malignancies. Although the …

T cells engineered to express chimeric antigen receptors (CARs) with tumor specificity have
shown remarkable success in treating patients with hematologic malignancies and …

Chimeric antigen receptor (CAR)-engineered T cells (CAR-T cells) have yielded
unprecedented efficacy in B cell malignancies, most remarkably in anti-CD19 CAR-T cells …

Chimeric antigen receptor (CAR) T cells are engineered constructs composed of synthetic
receptors that direct T cells to surface antigens for subsequent elimination. Many CAR …

The focus of cancer treatment has recently shifted toward targeted therapies, including
immunotherapy, which allow better individualization of care and are hoped to increase the …

T cells engineered to express chimeric antigen receptors (CARs) that are specific for tumour
antigens have led to high complete response rates in patients with haematologic …

Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary new pillar in cancer
treatment. Although treatment with CAR-T cells has produced remarkable clinical responses …